Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I.
Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.
PMID:34952708
Ovarian residual syndrome.
Bukovsky I, Liftshitz Y, Langer R, Weinraub Z, Sadovsky G, Caspi E.
Surg Gynecol Obstet. 1988 Aug;167(2):132-4.
PMID:3400031
Ovarian remnant syndrome.
Webb MJ.
Aust N Z J Obstet Gynaecol. 1989 Nov;29(4):433-5. doi: 10.1111/j.1479-828x.1989.tb01783.x.
PMID:2631678
DICER1 Tumor Predisposition.
Schultz KAP, Stewart DR, Kamihara J, Bauer AJ, Merideth MA, Stratton P, Huryn LA, Harris AK, Doros L, Field A, Carr AG, Dehner LP, Messinger Y, Hill DA.
2014 Apr 24 [updated 2020 Apr 30]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.